PEDIA-LAX ENEMA OTC
Generic Name and Formulations:
Monobasic sodium phosphate 9.5g, dibasic sodium phosphate 3.5g; per 59mL; latex-free; contains 2.2g sodium per enema.
Fleet, C.B., Company
Indications for PEDIA-LAX ENEMA:
Occasional constipation or bowel cleansing before rectal exam.
<2yrs: do not use. 2–4yrs: ½ enema rectally. 5–11yrs: 1 enema rectally. Results usually in 1–5 min; reevaluate if ineffective.
CHF. Ascites. Severe renal impairment. GI or GU obstruction. Megacolon. Imperforate anus.
Sodium-restricted diet. Impaired renal or cardiac function. Electrolyte disturbances. Colostomy. Discontinue if rectal bleeding or if no bowel movement occurs. Frequent use leads to dependence.
Electrolyte imbalances possible with calcium channel blockers, diuretics; use cautiously.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline